Refine
Document Type
- Article (6)
Language
- English (6)
Has Fulltext
- yes (6)
Is part of the Bibliography
- no (6)
Keywords
- - (6)
- human (3)
- gene expression (2)
- intestine (2)
- liver (2)
- protein abundance (2)
- CYP1A1 (1)
- CYP1A2 (1)
- cytochrome P450 (1)
- drug metabolizing enzymes (1)
- drug-drug interaction (1)
- drug–drug interaction (1)
- enzymes (1)
- expression (1)
- hepatic pathology (1)
- liver disease (1)
- localization (1)
- membrane transporters (1)
- metabolism (1)
- microRNA (1)
- nuclear receptors (1)
- organic cation transporter 1 (1)
- parotid gland (1)
- regulation (1)
- regulatory networks (1)
- saliva (1)
- transporters (1)
Institute
Publisher
- MDPI (5)
- Frontiers Media S.A. (1)
Salivary glands provide secretory functions, including secretion of xenobiotics and among
them drugs. However, there is no published information about protein abundance of drug transporters
measured using reliable protein quantification methods. Therefore, mRNA expression and absolute
protein content of clinically relevant ABC (n = 6) and SLC (n = 15) family member transporters in the
human parotid gland, using the qRT-PCR and liquid chromatography-tandem mass spectrometry
(LC−MS/MS) method, were studied. The abundance of nearly all measured proteins ranged between
0.04 and 0.45 pmol/mg (OCT3 > MRP1 > PEPT2 > MRP4 > MATE1 > BCRP). mRNAs of ABCB1,
ABCC2, ABCC3, SLC10A1, SLC10A2, SLC22A1, SLC22A5, SLC22A6, SLC22A7, SLC22A8, SLCO1A2,
SLCO1B1, SLCO1B3 and SLCO2B1 were not detected. The present study provides, for the first time,
information about the protein abundance of membrane transporters in the human parotid gland,
which could further be used to define salivary bidirectional transport (absorption and secretion)
mechanisms of endogenous compounds and xenobiotics.
Liver diseases are important causes of morbidity and mortality worldwide. The aim of
this study was to identify differentially expressed microRNAs (miRNAs), target genes, and key
pathways as innovative diagnostic biomarkers in liver patients with different pathology and functional
state. We determined, using RT-qPCR, the expression of 472 miRNAs in 125 explanted livers from
subjects with six different liver pathologies and from control livers. ANOVA was employed to
obtain differentially expressed miRNAs (DEMs), and miRDB (MicroRNA target prediction database)
was used to predict target genes. A miRNA–gene differential regulatory (MGDR) network was
constructed for each condition. Key miRNAs were detected using topological analysis. Enrichment
analysis for DEMs was performed using the Database for Annotation, Visualization, and Integrated
Discovery (DAVID). We identified important DEMs common and specific to the different patient
groups and disease progression stages. hsa-miR-1275 was universally downregulated regardless
the disease etiology and stage, while hsa-let-7a*, hsa-miR-195, hsa-miR-374, and hsa-miR-378 were
deregulated. The most significantly enriched pathways of target genes controlled by these miRNAs
comprise p53 tumor suppressor protein (TP53)-regulated metabolic genes, and those involved in
regulation of methyl-CpG-binding protein 2 (MECP2) expression, phosphatase and tensin homolog
(PTEN) messenger RNA (mRNA) translation and copper homeostasis. Our findings show a novel
panel of deregulated miRNAs in the liver tissue from patients with different liver pathologies. These
miRNAs hold potential as biomarkers for diagnosis and staging of liver diseases.
Intestinal transporter proteins are known to affect the pharmacokinetics and in turn the efficacy and safety of many orally administered drugs in a clinically relevant manner. This knowledge is especially well-established for intestinal ATP-binding cassette transporters such as P-gp and BCRP. In contrast to this, information about intestinal uptake carriers is much more limited although many hydrophilic or ionic drugs are not expected to undergo passive diffusion but probably require specific uptake transporters. A transporter which is controversially discussed with respect to its expression, localization and function in the human intestine is the organic cation transporter 1 (OCT1). This review article provides an up-to-date summary on the available data from expression analysis as well as functional studies in vitro, animal findings and clinical observations. The current evidence suggests that OCT1 is expressed in the human intestine in small amounts (on gene and protein levels), while its cellular localization in the apical or basolateral membrane of the enterocytes remains to be finally defined, but functional data point to a secretory function of the transporter at the basolateral membrane. Thus, OCT1 should not be considered as a classical uptake transporter in the intestine but rather as an intestinal elimination pathway for cationic compounds from the systemic circulation.
Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology
(2021)
Background: Unwanted drug-drug interactions (DDIs), as caused by the upregulation of clinically relevant drug metabolizing enzymes and transporter proteins in intestine and liver, have the potential to threaten the therapeutic efficacy and safety of drugs. The molecular mechanism of this undesired but frequently occurring scenario of polypharmacy is based on the activation of nuclear receptors such as the pregnane X receptor (PXR) or the constitutive androstane receptor (CAR) by perpetrator agents such as rifampin, phenytoin or St. John’s wort. However, the expression pattern of nuclear receptors in human intestine and liver remains uncertain, which makes it difficult to predict the extent of potential DDIs. Thus, it was the aim of this study to characterize the gene expression and protein abundance of clinically relevant nuclear receptors, i.e., the aryl hydrocarbon receptor (AhR), CAR, farnesoid X receptor (FXR), glucocorticoid receptor (GR), hepatocyte nuclear factor 4 alpha (HNF4α), PXR and small heterodimer partner (SHP), in the aforementioned organs. Methods: Gene expression analysis was performed by quantitative real-time PCR of jejunal, ileal, colonic and liver samples from eight human subjects. In parallel, a targeted proteomic method was developed and validated in order to determine the respective protein amounts of nuclear receptors in human intestinal and liver samples. The LC-MS/MS method was validated according to the current bioanalytical guidelines and met the criteria regarding linearity (0.1–50 nmol/L), within-day and between-day accuracy and precision, as well as the stability criteria. Results: The developed method was successfully validated and applied to determine the abundance of nuclear receptors in human intestinal and liver samples. Gene expression and protein abundance data demonstrated marked differences in human intestine and liver. On the protein level, only AhR and HNF4α could be detected in gut and liver, which corresponds to their highest gene expression. In transfected cell lines, PXR and CAR could be quantified. Conclusions: The substantially different expression pattern of nuclear receptors in human intestinal and liver tissue may explain the different extent of unwanted DDIs in the dependence on the administration route of drugs.